NCT00951405已完成2 期
An Exploratory Multi-Centre, Multi-National, Randomised, Double Blinded, Parallel Arm Trial Evaluating Safety, Pharmacokinetics and Dose-finding of Prophylactic Administration of Long Acting rFVIIa (LA-rFVIIa) in Haemophilia A or B Patients With Inhibitors
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 23
- 试验地点
- 1
- 主要终点
- Thrombogenecity
研究概览
简要总结
This trial is conducted in Asia, Europe, Japan and North America. The aim of this clinical trial is to investigate the safety and the efficacy of a prophylactic treatment option with long acting coagulation factor VII (LA-rFVIIa) for haemophilia patients with inhibitors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 12 Years 至 65 Years（Child, Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Male haemophilia A or B patients with inhibitors
- •Willing to undergo a bleeding preventive regimen of 3 months' duration and a total trial length of approximately 8 months
- •Historical or ongoing high titre inhibitor (more than or equal to 5 BU) based on either medical records, laboratory report reviews, patient and/or care provider interviews
- •At least 2 bleeding episodes requiring bypassing haemostatic-drug-based treatment within the last month or 12 bleeding episodes within the last 6 months prior to observation period
- •Body weight between 30 and 100 kg (both inclusive)
排除标准
- •Body Mass Index (BMI) above 30 kg/m2
- •Immune tolerance induction therapy within the last month prior to entering observation phase period
- •Known active pseudo tumours
- •Platelet count less than 50,000 platelets/microL (based on local laboratory value at screening visit)
- •Congenital or acquired coagulation disorders other than haemophilia A or B
- •Surgery within one month prior to the observation period. Catheter, stents and dental extractions do not count as surgeries, i.e. they will not exclude the patient. Port insertion is classified as surgery
- •Scheduled major and/or orthopaedic surgery, during the trial period until Follow up visit. Catheter, stents and dental extractions do not count as surgeries and will not exclude the patient. Port insertion is classified as surgery
- •Advanced atherosclerotic disease (i.e. known history of ischemic heart disease, or ischemic stroke)
- •Any clinical signs or known history of thromboembolic events incl. known deep vein thrombosis (DVT)
- •Known or clinically suspected allergy to activated recombinant human factor VII (NovoSeven®/NovoSeven RT®/Niastase®)
- •Prothrombin Time (PT) prolongation (30% above normal limits, or more than 5 seconds compared to control or International Normalised Range (INR) more than 1.7 as defined by local laboratory ranges at screening visit
- •Severe liver disease (ALAT more than 4 times of the upper limit of normal reference range) (as defined by local laboratory ranges) within a year of enrolment or at the screening
- •Clinical signs of renal dysfunction (dialysis) and/or creatinine levels more than or equal to 20% above upper normal limit (according to local laboratory range at the screening visit)
- •Dosing of any investigational drug within the last 30 days prior to the present trial
- •Any disease or condition which, according to the investigator's judgement, could imply a potential hazard to the subject, interfere with the trial participation or trial outcome
- •HIV positive patients who either have low CD4+ lymphocyte count ( 200/microL or less based on medical records within 6 months or laboratory screening at screening visit), or who are HCV-PCR positive (based on medical records), or who both have low CD4+ lymphocyte count (200/microL or less) and are HCV-PCR positive. If HCV-PCR testing is not locally available, a HIV positive patient who is HCV antibody positive cannot be included
- •Need to use other PEGylated pharmaceutical drug during the trial period
研究组 & 干预措施
A
Experimental
干预措施: activated recombinant human factor VII, long acting (Drug)
B
Experimental
干预措施: activated recombinant human factor VII, long acting (Drug)
C
Experimental
干预措施: activated recombinant human factor VII, long acting (Drug)
结局指标
主要结局
Thrombogenecity
时间窗: at all scheduled visits (1 - 9)
Immunogenecity: Neutralising Antibody Development
时间窗: at all scheduled visits (1 - 9)
次要结局
- AUC(0-48h) and AUC: Area under the FVIIa activity-time profile in the given time period, which is a measure of total blood exposure(at visit 2 and visit 7 until 48 hours after trial product administration)
- Annualized bleeding rates(During observation period; from visit 1 until visit 2 and treatment period; from visit 2 until visit 7. In total a period of 6 to 8 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725Congenital Bleeding DisorderCongenital FXIII DeficiencyNCT00978380Novo Nordisk A/S63
已完成
3 期
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome ResultsDiabetesDiabetes Mellitus, Type 2NCT01179048Novo Nordisk A/S9,341
已完成
2 期
Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma PatientsAcquired Bleeding DisorderTraumaNCT01563523Novo Nordisk A/S283
已完成
3 期
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia ACongenital Bleeding DisorderHaemophilia ANCT01138501Novo Nordisk A/S65
已完成
2 期
Haemophilia Patients With Inhibitors Being Treated for Acute Joint BleedsCongenital Bleeding DisorderHaemophilia AHaemophilia BNCT00486278Novo Nordisk A/S51